The Sickle-Cell Anemia Therapeutics Market in the United States: 2018 to 2022 - Led by Bristol-Myers Squibb, Emmaus Medical and Medunik USA - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 13, 2019--The “Sickle-Cell Anemia Therapeutics Market in the US 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.
Sickle-cell anemia treatment is associated with high cost medications in the US
To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care.
Recent product approvals for sickle-cell anemia
Due to fewer product availability in the US for the treatment of sickle-cell anemia, hence these recently approved products drive the market over the forecast period.
Limited number of approved drugs
The availability of very limited approved therapies for the treatment of sickle-cell anemia id the US is expected to hamper the growth of the market during our forecast period.
The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Key PlayersBristol-Myers Squibb Emmaus Medical Medunik USA
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry
PART 07: MARKET SEGMENTATION BY THERAPYComparison by therapy Hydroxyurea - Market size and forecast 2017-2022 L-glutamine therapy - Market size and forecast 2017-2022 Market opportunity by therapy
PART 08: CUSTOMER LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDSIntroduction of gene therapy Strategic alliances Orphan drug designations for sickle-cell anemia
PART 12: VENDOR LANDSCAPEOverview Landscape disruption
PART 13: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Emmaus Medical Medunik USA
For more information about this report visit https://www.researchandmarkets.com/research/rmbznc/the_sicklecell?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190213005442/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL PHYSICAL THERAPY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/13/2019 08:56 AM/DISC: 02/13/2019 08:56 AM